Showing 3121-3130 of 5646 results for "".
- Retina Consultants of America Continues Growth by Adding Pacific Northwest Retinahttps://modernod.com/news/retina-consultants-of-america-continues-growth-by-adding-pacific-northwest-retina/2480461/Retina Consultants of America (RCA), a
- Santen to Introduce First Plant-Derived Eye Drop Bottle in EMEA to Help Reduce Reliance on Fossil Fuel-Based Plastichttps://modernod.com/news/santen-to-introduce-first-plant-derived-eye-drop-bottle-in-emea-to-help-reduce-reliance-on-fossil-fuel-based-plastic/2480457/Santen unveiled plans to launch t
- Kala Pharmaceuticals Acquires Combangio, Maker of Regenerative Biotherapies for Severe Ocular Surface Diseaseshttps://modernod.com/news/kala-pharmaceuticals-acquires-combangio-maker-of-regenerative-biotherapies-for-severe-ocular-surface-diseases/2480449/Kala Pharmaceuticals announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex w
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- iVeena Announces Successful Completion of Pre-IND Meeting with FDAhttps://modernod.com/news/iveena-announces-successful-completion-of-pre-ind-meeting-with-fda/2480426/iVeena Delivery Systems announced completion of a pre-investigational new drug (IND) meeting with the FDA regarding the development plan for a novel pharmacologic treatment of pediatric myopia. IVMED-85 enables physiologic crosslinking in the sclera an
- Johnson & Johnson Vision to Present New Data at AAO Demonstrating Benefits That New Innovations in Cataract Surgery Will Provide to Physicians and Patientshttps://modernod.com/news/johnson-johnson-vision-to-present-new-data-at-aao-demonstrating-benefits-that-new-innovations-in-cataract-surgery-will-provide-to-physicians-and-patients/2480412/Johnson & Johnson Vision will present a range of company-sponsored studies supporting new innovations in its cataract
- AI-Powered Glaucoma Screening Test Delivers Rapid Resultshttps://modernod.com/news/ai-powered-glaucoma-screening-test-delivers-rapid-results/2480378/
- MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platformhttps://modernod.com/news/meiragtx-announces-the-presentation-of-two-novel-inherited-retinal-disease-ird-programs-and-riboswitch-gene-regulation-platform/2480359/MeiraGTx announced three poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress. Two preclinical programs addressing inherited retinal diseases (IRDs) caused by mutations in KCNV2 and GUCY2D are presented with
- Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsidshttps://modernod.com/news/atsena-therapeutics-unveils-xlrs-gene-therapy-program-leveraging-novel-spreading-capsids/2480355/Atsena Therapeutics unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene. XLRS is characterized by schisis, or abnormal splitting of the layers of the retina, which causes impa
- New 4-Year Data Show Genentech’s Enspryng Significantly Reduces Debilitating Relapses in People with NMOSDhttps://modernod.com/news/new-4-year-data-show-genentechs-enspryng-significantly-reduces-debilitating-relapses-in-people-with-neuromyelitis-optica-spectrum-disorder/2480350/Genentech announced new longer-term efficacy and safety data for Enspryng (satralizumab-mwge). The data show Enspryng has a favorable benefit-risk profile and is effective in reducing relapses over 4 years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD, a